PDCD1 and cancer: TAMs appear to be an important potential target for cancer therapy, also new possibilities for improving the efficacy of anti-PD-1 monoclonal antibodies (Bouhlel et al., 2007; Orecchioni et al., 2019; Wang C. et al., 2021).